Phathom Pharmaceuticals, Inc. develops and commercializes treatments for gastrointestinal diseases, with news centered on VOQUEZNA® (vonoprazan), an oral potassium-competitive acid blocker. Company updates commonly cover VOQUEZNA commercialization for GERD, prescription trends, product presentations, clinical and real-world data, and vonoprazan use with antibiotics for H. pylori infection.
Recurring announcements also address financial results, expense discipline, balance-sheet actions, and guidance tied to the company's commercial execution. Phathom's pipeline-related updates include studies evaluating VOQUEZNA in eosinophilic esophagitis and publications or conference presentations involving GERD and non-erosive reflux disease.
Phathom Pharmaceuticals (PHAT) urged people with recurring heartburn to talk with their healthcare provider as part of GERD Awareness Week, November 22–28, 2026.
Heartburn two or more times a week may be a sign of gastroesophageal reflux disease (GERD), which affects an estimated 65 million Americans. Phathom released a holiday heartburn myths-and-facts infographic and is continuing its #GERDtoKnow education series on LinkedIn and X throughout November. The company also continues to expand patient support resources designed to help people navigate treatment and access challenges.
Phathom Pharmaceuticals (Nasdaq: PHAT) management is scheduled to participate in three investor conferences in November, beginning November 10, 2026.
Fireside chats are scheduled at Guggenheim in Boston on November 10 at 3:00 p.m. EST; Stifel in New York on November 11 at 8:40 a.m. EST; and Jefferies in London on November 18 at 10:30 a.m. EST / 3:30 p.m. GMT. Management will also participate in one-on-one meetings at each conference.
Phathom Pharmaceuticals (Nasdaq: PHAT) announced that eligible commercially insured patients may now pay as little as $0 for VOQUEZNA exclusively through BlinkRx. The offer covers 30-, 60- or 90-day supplies of 10 mg or 20 mg tablets, subject to eligibility requirements, benefit limits and program terms.
Patients must be at least 18 and have commercial insurance covering VOQUEZNA. Government-program prescriptions and Massachusetts residents are excluded from the $0 offer. Eligible commercially insured Massachusetts residents may pay as little as $25, $50 or $90 for 30-, 60- or 90-day supplies using the savings card. Eligible retail-pharmacy patients may continue to pay as little as $25 for 30 days. BlinkRx also offers eligible uninsured patients, or those without VOQUEZNA coverage, a cash-pay option starting at $55 for 30 days, plus free home delivery and insurance-authorization support.
Phathom Pharmaceuticals (PHAT) reported third-quarter 2026 net revenue of $84.7 million, up 71% from the same period last year. Revenue increased 14% sequentially. The GAAP net loss narrowed to $13.9 million from $30.0 million, and operating cash flow was positive for a second consecutive quarter. Cash reached $184.6 million at September 30, up $2.1 million sequentially.
VOQUEZNA prescriptions exceeded 2 million through October 16. Phathom reaffirmed 2026 guidance: revenue of $310–325 million, gross-to-net discounts of 55–59%, gross margin of approximately 80%, and non-GAAP operating expenses of $235–245 million, excluding stock-based compensation. The first participant has been dosed in the Phase 3 study of as-needed VOQUEZNA for non-erosive reflux disease. Phathom expects results in the first quarter of 2028 and Phase 2 eosinophilic esophagitis results in the fourth quarter of 2026.
Summary not available.
Summary not available.
Phathom Pharmaceuticals (PHAT) will report third quarter 2026 financial results and provide a business update on October 29, 2026.
Management will host a live webcast at 8:00 am EDT, accessible through the Events & Presentations section of the company’s website. A recording will remain available for 90 days after the call.
Phathom Pharmaceuticals (PHAT) presented new VOQUEZNA cost-effectiveness projections and clinical analyses for gastroesophageal reflux disease (GERD) at ACG 2026.
Phathom's lifetime model projected healthcare savings versus proton pump inhibitors at an estimated net price in overall and severe Erosive GERD. At wholesale acquisition cost, incremental costs per quality-adjusted life year—a measure combining survival and quality of life—were $28,402 and $18,878, respectively. The model projected fewer downstream complications and incorporated drug-pricing and cost assumptions.
A post-hoc Phase 3 analysis found improved heartburn control versus placebo across body mass index subgroups, with no significant treatment-by-BMI interaction. A retrospective study found more severe baseline GERD among VOQUEZNA initiators than prescription PPI initiators. Researchers also presented 38 independent abstracts on vonoprazan.
Phathom Pharmaceuticals (PHAT) will present three VOQUEZNA scientific posters at the ACG Annual Scientific Meeting, held October 9–14, 2026, in Nashville.
The presentations cover gastroesophageal reflux disease (GERD): an analysis of efficacy across body mass index subgroups in Non-Erosive GERD, a retrospective review of real-world patient characteristics, and a model comparing lifetime cost-effectiveness with proton pump inhibitors in adults with Erosive Esophagitis. The posters are scheduled for October 11, 12 and 13, respectively. Phathom will also host a Product Theater on VOQUEZNA’s clinical efficacy and safety, featuring clinical cases and patient perspectives.
Phathom Pharmaceuticals (PHAT) has begun patient screening for a Phase 3 study of as-needed VOQUEZNA for non-erosive GERD. The randomized, double-blind study will compare VOQUEZNA 10 mg with placebo and is expected to enroll approximately 500 adults who report heartburn at least four days per week. It is planned for approximately 80 U.S. sites. The primary measure, assessed at Week 12, is the percentage of heartburn episodes with complete relief within two hours that lasts for 24 hours after dosing.
The study follows previously reported positive Phase 2 results. Phathom expects topline results in the first quarter of 2028. If the Phase 3 study succeeds, the company intends to use it to support a potential submission seeking to add as-needed treatment to VOQUEZNA’s label. VOQUEZNA is already approved for relief of heartburn associated with non-erosive GERD, but the as-needed regimen remains investigational.